The promise and pitfalls of composite endpoints in sepsis and COVID-19 clinical trials. Brown, P. M., Rogne, T., & Solligård, E. Pharmaceutical Statistics, 20(2):413–417, 2021. _eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/pst.2070![The promise and pitfalls of composite endpoints in sepsis and COVID-19 clinical trials [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex Composite endpoints reveal the tendency for statistical convention to arise locally within subfields. Composites are familiar in cardiovascular trials, yet almost unknown in sepsis. However, the VITAMINS trial in patients with septic shock adopted a composite of mortality and vasopressor-free days, and an ordinal scale describing patient status rapidly became standard in COVID studies. Aware that recent use could incite interest in such endpoints, we are motivated to flag their potential value and pitfalls for sepsis research and COVID studies.
@article{brown_promise_2021,
title = {The promise and pitfalls of composite endpoints in sepsis and {COVID}-19 clinical trials},
volume = {20},
copyright = {© 2020 The Authors. Pharmaceutical Statistics published by John Wiley \& Sons Ltd.},
issn = {1539-1612},
url = {http://onlinelibrary.wiley.com/doi/abs/10.1002/pst.2070},
doi = {https://doi.org/10.1002/pst.2070},
abstract = {Composite endpoints reveal the tendency for statistical convention to arise locally within subfields. Composites are familiar in cardiovascular trials, yet almost unknown in sepsis. However, the VITAMINS trial in patients with septic shock adopted a composite of mortality and vasopressor-free days, and an ordinal scale describing patient status rapidly became standard in COVID studies. Aware that recent use could incite interest in such endpoints, we are motivated to flag their potential value and pitfalls for sepsis research and COVID studies.},
language = {en},
number = {2},
urldate = {2021-03-07},
journal = {Pharmaceutical Statistics},
author = {Brown, P. M. and Rogne, Tormod and Solligård, Erik},
year = {2021},
note = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/pst.2070},
keywords = {compound-endpoints, covid19, multiple-endpoints, rct, sepsis},
pages = {413--417},
}
Downloads: 0
{"_id":"Qwon5GtaZFLxzFX6m","bibbaseid":"brown-rogne-solligrd-thepromiseandpitfallsofcompositeendpointsinsepsisandcovid19clinicaltrials-2021","authorIDs":[],"author_short":["Brown, P. M.","Rogne, T.","Solligård, E."],"bibdata":{"bibtype":"article","type":"article","title":"The promise and pitfalls of composite endpoints in sepsis and COVID-19 clinical trials","volume":"20","copyright":"© 2020 The Authors. Pharmaceutical Statistics published by John Wiley & Sons Ltd.","issn":"1539-1612","url":"http://onlinelibrary.wiley.com/doi/abs/10.1002/pst.2070","doi":"https://doi.org/10.1002/pst.2070","abstract":"Composite endpoints reveal the tendency for statistical convention to arise locally within subfields. Composites are familiar in cardiovascular trials, yet almost unknown in sepsis. However, the VITAMINS trial in patients with septic shock adopted a composite of mortality and vasopressor-free days, and an ordinal scale describing patient status rapidly became standard in COVID studies. Aware that recent use could incite interest in such endpoints, we are motivated to flag their potential value and pitfalls for sepsis research and COVID studies.","language":"en","number":"2","urldate":"2021-03-07","journal":"Pharmaceutical Statistics","author":[{"propositions":[],"lastnames":["Brown"],"firstnames":["P.","M."],"suffixes":[]},{"propositions":[],"lastnames":["Rogne"],"firstnames":["Tormod"],"suffixes":[]},{"propositions":[],"lastnames":["Solligård"],"firstnames":["Erik"],"suffixes":[]}],"year":"2021","note":"_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/pst.2070","keywords":"compound-endpoints, covid19, multiple-endpoints, rct, sepsis","pages":"413–417","bibtex":"@article{brown_promise_2021,\n\ttitle = {The promise and pitfalls of composite endpoints in sepsis and {COVID}-19 clinical trials},\n\tvolume = {20},\n\tcopyright = {© 2020 The Authors. Pharmaceutical Statistics published by John Wiley \\& Sons Ltd.},\n\tissn = {1539-1612},\n\turl = {http://onlinelibrary.wiley.com/doi/abs/10.1002/pst.2070},\n\tdoi = {https://doi.org/10.1002/pst.2070},\n\tabstract = {Composite endpoints reveal the tendency for statistical convention to arise locally within subfields. Composites are familiar in cardiovascular trials, yet almost unknown in sepsis. However, the VITAMINS trial in patients with septic shock adopted a composite of mortality and vasopressor-free days, and an ordinal scale describing patient status rapidly became standard in COVID studies. Aware that recent use could incite interest in such endpoints, we are motivated to flag their potential value and pitfalls for sepsis research and COVID studies.},\n\tlanguage = {en},\n\tnumber = {2},\n\turldate = {2021-03-07},\n\tjournal = {Pharmaceutical Statistics},\n\tauthor = {Brown, P. M. and Rogne, Tormod and Solligård, Erik},\n\tyear = {2021},\n\tnote = {\\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/pst.2070},\n\tkeywords = {compound-endpoints, covid19, multiple-endpoints, rct, sepsis},\n\tpages = {413--417},\n}\n\n","author_short":["Brown, P. M.","Rogne, T.","Solligård, E."],"key":"brown_promise_2021","id":"brown_promise_2021","bibbaseid":"brown-rogne-solligrd-thepromiseandpitfallsofcompositeendpointsinsepsisandcovid19clinicaltrials-2021","role":"author","urls":{"Paper":"http://onlinelibrary.wiley.com/doi/abs/10.1002/pst.2070"},"keyword":["compound-endpoints","covid19","multiple-endpoints","rct","sepsis"],"downloads":0},"bibtype":"article","biburl":"https://api.zotero.org/groups/2199991/items?key=lvYOaZITy5xmJTj2Chg8pvSV&format=bibtex&limit=100","creationDate":"2021-03-21T22:45:08.707Z","downloads":0,"keywords":["compound-endpoints","covid19","multiple-endpoints","rct","sepsis"],"search_terms":["promise","pitfalls","composite","endpoints","sepsis","covid","clinical","trials","brown","rogne","solligård"],"title":"The promise and pitfalls of composite endpoints in sepsis and COVID-19 clinical trials","year":2021,"dataSources":["fGxngGYXSjSNcMccW"]}